Furthermore, autophagy has been observed in osimertinib-treated NSCLC cells that harbor wild-type EGFR and in cells that harbor EGFR mutations, L858R/T790M, through increased levels of LC3 and a reduced expression of p62/SQSMT1 [108]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.